Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Merus N.V. is a clinical-stage immuno-oncology company dedicated to the discovery and development of innovative multispecific antibody therapeutics, known as Multiclonics®. These therapies are designed to harness the power of the immune system to treat cancer patients. Merus focuses on bispecific and trispecific antibodies that engage multiple targets simultaneously, aiming for improved efficacy and safety profiles compared to conventional treatments. Their proprietary Biclonics® and Triclonics® platforms enable the rapid generation and manufacturing of these complex molecules.
Global headquarters, housing primary research and development labs, corporate strategy, and administrative functions supporting Merus's worldwide operations.
Strategically located in the Utrecht Science Park, a leading European hub for biomedical research and innovation, fostering collaboration and access to talent.
Emphasizes scientific rigor, innovation, and collaboration. Employees are driven by a mission to develop life-changing therapies for cancer patients in a dynamic and research-focused setting.
Central to Merus's R&D capabilities, leveraging the strong life sciences ecosystem of Utrecht to advance its pipeline of bispecific and trispecific antibodies.
Merus N.V. operates primarily from its headquarters in Utrecht, Netherlands, and its U.S. office in Watertown, Massachusetts. While its physical office presence is concentrated, its clinical trials and collaborations often have a global reach, involving sites and partners across North America, Europe, and Asia to advance its pipeline of cancer immunotherapies.
Padualaan 8
Utrecht
Utrecht
Netherlands
Address: 321 Arsenal Street, Suite 102, Watertown, MA 02472
To advance clinical trials, engage with regulatory bodies like the FDA, and build strategic partnerships within the U.S. biotechnology and pharmaceutical landscape.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Merus N.V.' leadership includes:
Merus N.V. has been backed by several prominent investors over the years, including:
Merus N.V. experienced key leadership changes in the past year, including the appointment of a new Chief Financial Officer and the departure of its Chief Business Officer, reflecting strategic adjustments in its executive team.
Discover the tools Merus N.V. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Merus N.V. commonly uses the email format combining the employee's first name and last name, separated by a dot, followed by @merus.nl. Other variations might exist but this is a widely observed pattern.
[first].[last]@merus.nl
Format
jane.doe@merus.nl
Example
80%
Success rate
Merus N.V. Press Release • May 16, 2024
Merus N.V. announced a publication in Nature Communications detailing preclinical data for MCLA-129, its bispecific antibody targeting EGFR and c-MET, demonstrating its potential in treating solid tumors, particularly non-small cell lung cancer (NSCLC)....more
Merus N.V. Press Release • May 7, 2024
Merus reported its financial results for Q1 2024, highlighting progress in its clinical pipeline, including updates on Zeno (zenocutuzumab), Petosemtamab, and MCLA-129, and reiterated its financial guidance for the year....more
Merus N.V. Press Release • April 22, 2024
Merus N.V. announced the appointment of Björn van der Vlist as Chief Financial Officer, effective April 22, 2024. Mr. van der Vlist brings over 20 years of experience in finance and leadership roles in the life sciences industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Merus N.V., are just a search away.